COMMUNIQUÉS West-GlobeNewswire

Stereotaxis Reports 2025 Full Year Financial Results
09/03/2026
ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth [...]
Xenon Pharmaceuticals Announces Proposed Public Offering
09/03/2026
VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical [...]
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
09/03/2026
NEW YORK and WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation [...]
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
09/03/2026
Please see enclosed pdf. Attachment 09032026_trading_in_shares_NBC
Kristen Boehmer of Empowered Lyfe Partners with MD Logic Health to Launch Daily Colostrum, an Advanced Low Molecular Weight Bioactive Colostrum
09/03/2026
Miami, FL, March 09, 2026 (GLOBE NEWSWIRE) -- As consumer awareness surrounding the connection between gut health and overall wellness continues to rise, demand for simple, high-quality, science-backed solutions is [...]
MemoTril Consumer Concerns Under Investigation: Critiquing The Memo Tril Claims
09/03/2026
A 2026 consumer research report examining MemoTril marketing claims, ingredient transparency, refund policies, manufacturing disclosures, and verification considerations for adults researching cognitive support [...]
FocusMax Cognitive Support Claims Evaluated: Latest 2026 Consumer Research Report on FocusMax Ingredients, Proprietary Blend Dosing, and Cognitive Supplement Research
09/03/2026
A 2026 informational consumer research report examining FocusMax cognitive support marketing claims, ingredient-level research context, proprietary blend transparency, pricing disclosures, and verification [...]
Choice Healthcare Services Announces Expansion of Children’s Choice Pediatric Dentistry Locations in California
09/03/2026
Two Locations to Launch New, Enhanced Offices in 2026 for Greater Patient Comfort and Accessibility Sacramento, CA, March 09, 2026 (GLOBE NEWSWIRE) -- Choice Healthcare Services , the parent company of Children’s Choice [...]
VisiFlora Gut-Eye Vision Support Claims Examined: 2026 Consumer Report on the 22-Ingredient Formula, Gut-Eye Axis Research, and What Adults Researching Vision Supplements Should Verify
09/03/2026
A 2026 informational consumer research report examining VisiFlora's gut-eye axis positioning, ingredient research context, 22-ingredient formula structure, pricing disclosures, and independent verification [...]
The Great Give Back brings community together in support of Royal Columbian Hospital
09/03/2026
NEW WESTMINSTER, British Columbia, March 09, 2026 (GLOBE NEWSWIRE) -- Royal Columbian Hospital Foundation is inviting the community to come together for The Great Give Back, presented by Pan American Silver , a free, [...]
Update: Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
09/03/2026
PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik ® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision to withdraw is [...]
Update: Ipsen retire volontairement Tazverik® (tazemetostat) dans le traitement du lymphome folliculaire et du sarcome épithélioïde
09/03/2026
PARIS, FRANCE, 09 mars 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd'hui le retrait volontaire de Tazverik ® (tazemetostat) des marchés où il est commercialisé par Ipsen, et dans toutes les indications. La [...]
Radiant Health Centers Announces Honorees for 40th Annual Gala Celebrating Four Decades of Compassionate Care
09/03/2026
Jai Rodriguez and Harper Steele Headline Evening Honoring Cultural Impact, Legacy Leadership, and Community Hope Irvine, CA, March 09, 2026 (GLOBE NEWSWIRE) -- Radiant Health Centers , Orange County’s largest provider [...]
GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF
09/03/2026
FDA grants Orphan Drug Designation (ODD) for NTZ for ACLF, a severe condition with no approved therapies NTZ is being advanced in ACLF through its G1090N reformulation, designed to unlock its clinical potential for [...]
GENFIT reçoit la désignation Orphan Drug de la FDA pour NTZ dans le traitement de l’ACLF
09/03/2026
La FDA accorde la désignation Orphan Drug (ODD) à NTZ dans l'ACLF, syndrome grave pour lequel il n'existe aucun traitement approuvé NTZ est développé dans l'ACLF via sa nouvelle formulation G1090N, conçue pour optimiser [...]
EssilorLuxottica: Disclosure of transactions in own shares
09/03/2026
Disclosure of transactions in own shares Paris, France (March 9, 2026 - 6:00 pm) – In accordance with the authorization granted by the Annual Shareholders’ Meeting on April 30, 2025, EssilorLuxottica declares that from [...]
EssilorLuxottica: Déclaration de transactions sur actions propres
09/03/2026
Déclaration de transactions sur actions propres Paris, France (9 mars 2026, 18h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 30 avril 2025, EssilorLuxottica déclare que du 2 mars 2026 au 4 [...]
Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026
09/03/2026
Lyon (France), March 9 , 202 6 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its full year 2025 financial results on Wednesday, March 18, 2026. The [...]
Valneva publiera ses résultats financiers consolidés 2025 le 18 mars 2026
09/03/2026
Lyon (France), le 9 mars 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA, société spécialisée dans les vaccins, a annoncé aujourd'hui qu’elle publiera ses résultats financiers pour l’exercice 2025 le mercredi 18 [...]

Pages